Kornimate/medical-research-clean huggingface dataset:
interest of relaxation from patients with pain due to migraine

Conditions: Migraine

Summary: the purpose of this study is to determine whether relaxation (autogenic training of schultz) is effective in treatment for migraine.

this randomized, multicenter study compares 2 parallel groups of patients with migraine : * i: patients are treated with relaxation + medical treatment (beta-bloquant or oxetorone)+ patients' education * ii: patients are treated only with medical treatment + patients' education. visit 1 : 1 month before randomization for patient's selection and baseline data visit 2 (j0): inclusion (randomization) during the first 2 months patients from group i benefit from relaxation consultations. visit 3 (2 months after randomization)and visit 4 (4 months after randomization) : evaluation of the efficacy of the two treatment strategies. primary endpoint : - number of days with migraine per month from j0 to visit 4. secondary endpoints : * monthly drug consumption * percentage of patients who respond (50 % frequency reduction) * quality of life (sf 36) each day, patients note in a notebook if a migraine appears and its intensity.

Eligibility criteria:
inclusion criteria: * age \> 18 years * 5 to 14 days of migraines per month exclusion criteria: * headache by medication abuse * patients who already know relaxation technics * depression * contra indication of using beta-bloquant or oxetorone

Keywords: relaxation (schultz) migraine antipain center
injectable poly-l-lactic acid for treatment of hill and valley acne scarring

Conditions: Acne Vulgaris

Summary: primary: evaluate the degree of correction attainable with poly-l-lactic acid(sculptra) for the correction of hill and valley acne scarring secondary: document types and incidence of device adverse events with poly-l-lactic acid(sculptra) therapy.


Eligibility criteria:
inclusion criteria: * outpatient seeking therapy for correction of hill and valley acne scarring. * ability and willingness to understand and comply with requirements of the trial exclusion criteria: * the subject has active acne or chronic skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster * history of presence of keloid formation or hypertrophic scars * history of procedures that precipitate an active dermal inflammatory or hyperplastic response (i.e., epilation or radiofrequency laser and chemical peeling procedures) within one month of study entry * history of use of facial tissue augmenting therapy or aesthetic facial surgical therapy within six months prior to study entry * concomitant anticoagulant therapy, antiplatelet therapy or has any bleeding disorders * history of unanticipated adverse reactions when treated with hyaluronic acid based products * any condition which in the opinion of the investigator makes the patient unable to complete the study per protocol (e.g., patients not likely to avoid other facial cosmetic treatments; patients not likely to stay in the study for its duration because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable, or patients who have a concomitant condition that may develop symptoms that might confuse or confound study treatments or assessments) * history of or current cancerous or pre-cancerous lesions in the area to be treated * use of any investigational drugs or any other medical devices within 30 days of enrolment * use of any prohibited medication within a proscribed time period before entry * pregnancy * recent use of accutane (patient should not be on accutane for the last 6 months) * history of allergic/anaphylactic reactions, including hypersensitivity to local anaesthetics (lidocaine) * recent history of trauma in the face (less that 1 year) * previous of dermalive or dermadeep the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
nature-oriented chatbots on older adults' mental health

Conditions: Depression; Loneliness; Happiness; Connection With Nature; Anxiety

Summary: this study aims to explore the influence of nature-oriented chatbots on the mental health of older adults residing alone. leveraging the therapeutic potential of nature exposure and the interactive capabilities of chatbot technology, our research seeks to investigate whether engaging with nature-oriented chatbots can mitigate feelings of depression, and loneliness while enhancing overall psychological well-being and quality of life. through a combination of experimental interventions and psychological assessments, the investigators will assess the impact of nature-oriented chatbots on participants' mental health outcomes.


Eligibility criteria:
inclusion criteria: 1. individuals aged 60 years and above who live alone. 2. regular users of smartphones, with internet access, and proficient in using line. 3. individuals who consent to participate in the study and sign the consent form. 4. capable of understanding interactive messages and the content of pre- and post-test questionnaires. exclusion criteria: 1. individuals without smartphones, internet access, or not using line. 2. diagnosed with sensory impairments. 3. diagnosed with mental illnesses requiring continuous treatment.
the headache inducing effects of cilostazol on migraine patients

Conditions: Migraine

Summary: we will use cilostazol as a tool to investigate its headache inducing effects in migraine patients.


Eligibility criteria:
inclusion criteria: * diagnosed with migraine without aura according to the ihs criteria from 2004. * healthy besides migraine exclusion criteria: * tension-type headache more than 3 days per month * other types of primary headaches * pregnancy * history of vascular diseases or psychiatric diseases.
aspergillusone-health: deciphering azole resistance in aspergillus fungi using a one health approach

Conditions: Aspergillus Fumigatus Infection

Summary: during a two year prospective study onpatients from department's hospitals and centralized by the pneumology department nantes ch,all respiratory clinical samples will be cultivated for aspergillus isolation (2900aspergillusisolates) as standard care. the azole susceptibility pattern of isolates will be determined to itraconazole, voriconazole by subculture on azole- enriched medium at 35°c as primary screen and resistance confirmed by eucast reference metho.in parallel, the relevance of detecting resistance (tr34 and tr46) directly in culture-negative bal respiratory samples by a qpcr method will be studied in an attempt to reach a greater exhaustiveness of the resistance phenomeno. in case of azole-resistant isolate,patient data such as the underlying disease,date and site of aspergillus isolation,disease classification,previous azole drug exposure,and home and work geographic allocation,occupation of the patient will be collecte. for all other aspergillus occurrences, underlying disease, previous azole drug exposure,home and work location of the patient will be collected in an attempt to identify risk factor.


Eligibility criteria:
inclusion criteria: * patient over 18 years of age * patient who has given his or her consent to participate in the study * patient affiliated to a social security scheme * patient with a respiratory sample taken between 2020 and 2023 for the retrospective cohort and from 2024 for the prospective cohort in which aspergillus has been isolated * patients living in the loire atlantique and vendée regions exclusion criteria: * patient under guardianship or legal protection * patient of no fixed adress
misight 1 day safety post-approval study

Conditions: Myopia

Summary: the purpose of this post-approval study is to confirm the safety of daily disposable soft contact lens wear among the intended patient population for the misight 1 day lens in the us.

this prospective post-approval study of safety in a us study population is to confirm the safety of misight 1 day lenses. consecutive subjects receiving the misight 1 day lens, who meet the inclusion criteria, will be prospectively offered to participate in the study. additionally, safety data from the misight 1 day post-approval study for effectiveness and visual symptoms (pas001) will be used to supplement this safety study.

Eligibility criteria:
inclusion criteria: 1. be between 8 and 12 years of age inclusive at the time of enrollment. 2. manifest refraction - spherical equivalent refractive error (sere) at baseline between -0.50 d and -7.00 d inclusive (at the corneal plane). 3. best-corrected visual acuity by manifest refraction of at least 20/25 bilaterally 4. free of ocular disease or abnormalities (including any corneal scar) 5. the parent/guardian must be capable of comprehending the nature of the study and consent to the use and release of their child's de-identified health care encounter data to be used for purposes of this study. assent will be obtained from the child in a manner specified by the irb. 6. parent/guardian must sign the release of medical records associated with the outcomes of interest identified from claims data. 7. interested in wearing contact lenses for approximately 10 hours per day and 6 days per week. 8. possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses. exclusion criteria: 1. acute and subacute inflammation or infection of the anterior chamber of the eye. 2. any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids. 3. severe insufficiency of lacrimal secretion (dry eyes). 4. corneal hypoesthesia (reduced corneal sensitivity), if not aphakic. 5. any systemic disease that may affect the eye or be exaggerated by wearing contact lenses. 6. allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions. 7. any active corneal infection (bacterial, fungal, or viral). 8. if eyes are red or irritated. 9. the patient is unable to follow lens handling and wear regimen or unable to obtain assistance to do so. 10. in addition to the labeling contraindications, children who are under medication that would interfere with contact lens wear, or who are using any pharmaceuticals for control of myopia will not be included in the study.
treatment of women with hyperandrogenic pcos with two different ratios of myo-inositol:d-chiro-inositol: a comparison

Conditions: Polycystic Ovarian Syndrome (PCOS)

Summary: in this study, female patients diagnosed with polycystic ovary syndrome (pcos) will be enrolled. in particular, those with elevated testosterone or with clinical signs of hyperandrogenism, along with menstrual cycle alterations and/or polycystic ovary morphology at ultrasound, will be included in the study. current treatments for pcos include insulin sensitizers (such as metformin) and hormonal contraceptives. however, they are not devoid of side effects or may not be well tolerated, often leading to therapy discontinuation. inositol represents a valid alternative to standard treatments, as it serves both as insulin sensitizer and as second messenger of fsh in the ovaries, thus regulating glucose metabolism and supporting ovarian function. the presence of two inositol isomers, namely myo-inositol and d-chiro-inositol, in defined ratios in human tissues suggests that supplementation with both would be ideal. despite numerous evidence available, the ratio that gives the best clinical results is still debated. in the present clinical trial, patients will be given a dietary supplement containing myo-inositol and d-chiro-inositol in two ratios (either 40:1 or 3.6:1, respectively) for three months. restoration of regular menstrual cycle and of hormonal status will be the primary goal of the intervention.


Eligibility criteria:
inclusion criteria: * pcos according to the rotterdam criteria * clinical or biochemical hyperandrogenism exclusion criteria: * other causes of ovulatory disfunction (e.g., hyperprolactinemia or hypothyroidism) * other causes of hyperandrogenism (e.g., adrenal hyperplasia or cushing's syndrome) * use of medications that influence ovulation * hormonal treatments * chronic pharmacological therapies * use of inositol-containing supplements * regular consumption of inositol-enriched food

Keywords: pcos myo-inositol d-chiro-inositol menstual cycle
sc1011 twice daily vs placebo in patients diagnosed with idiopathic pulmonary fibrosis (ipf)

Conditions: Idiopathic Pulmonary Fibrosis

Summary: evaluating sufenidone (sc1011) in ipf patients for efficacy and safety. includes screening, treatment, and follow-up, with fvc decline and health checks.

randomized, double-blind study comparing sufenidone (sc1011) and placebo in ipf patients, with interim analysis at 26 weeks to select the optimal dose for a 52-week treatment period followed by 4-week safety monitoring

Eligibility criteria:
inclusion criteria: * ability to understand and sign written informed consent. * the diagnosis time of ipf before enrollment was less than 5 years. * combination of high resolution computerized tomography (hrct) pattern, and if available surgical lung biopsy pattern, as assessed by central reviewers, are consistent with diagnosis of ipf. * dlco (corrected for hb): 30%-90% predicted of normal. * fvc\>= 50% predicted of normal. exclusion criteria: * forced expiratory volume in one second (fev1)/fvc ratio \<0.7 after administration of bronchodilator at screening * expected to receive a lung transplant within 1 year from randomization or, for patients at sites in the united states, on a lung transplant waiting list at randomization. * known explanation for interstitial lung disease * history of asthma or chronic obstructive pulmonary disease * active infection * ongoing ipf treatments including investigational therapy, immunosuppressants, and cytokine modulating agents * history of unstable or deteriorating cardiac or pulmonary disease (other than ipf) within the previous 6 months

Keywords: pulmonary fibrosis idiopathic pulmonary fibrosis lung diseases respiratory tract diseases
preliminary study of the sagittal alignment of the lumbo-pelvic complex in a sitting position

Conditions: Back Pain; Low Back Pain

Summary: the main objective of this study is to investigate the influence of seat type (straight chair versus "ergonomic" chair) on the sagittal alignment of the lumbo-pelvic complex in two different postures compared to standing for each individual in both a chronic-back-pain and a non-chronic-back-pain population.


Eligibility criteria:
general inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan inclusion criteria for the chronic back pain group * patient has chronic lombalgia (\> 3 months) * patient has discopathy evidenced by standard imaging of the lumbar spine inclusion criteria for the non chronic back pain group * patient does not have chronic lombalgia or neurological symptoms * patients hospitalized for cardiovascular physical therapy which does not interfere with the sagital alignment of the lombo-pelivien complex (post-infarctus care, cardiac insufficiency) exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the subject has had more than two x-rays, or similar ray exposure during the previous year * the subject has a professional activity or hobby that exposes him/her to radiation * the subject has a lombo-pelivien malformation
efficacy and safety of celecoxib versus placebo in the treatment of patients with osteoarthritis of the knee who were unresponsive to naproxen and ibuprofen

Conditions: Osteoarthritis, Knee

Summary: to compare the safety and efficacy of celecoxib versus placebo in the treatment of patients with knee osteoarthritis who were unresponsive to treatment with prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen


Eligibility criteria:
inclusion criteria: * oa of the knee in flare state at baseline visit and functional capacity class of i-iii * failed adequate trials of both naproxen and ibuprofen (prescription strength) within the past 5 years due to lack of efficacy, tolerability or both; duration of prescription strength ibuprofen and naproxen must have been a minimum of 2 weeks for each drug at the respective recommended doses if failure was due to lack of efficacy, and for any duration if failure was due to lack of tolerability exclusion criteria: * inflammatory arthritis or gout/pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded) * received acetaminophen within 24 hours of baseline visit * use of mobility assisting device for less than six weeks prior to study screening or use of a walker * history of gastrointestinal (gi) perforation, obstruction, or bleeding * diagnosed or treated for gi ulcer within 60 days prior to first dose of study medication * recieved corticosteroids or hyaluronic acid within certain timeframe before study
chemotherapy with low-dose radiation for pediatric hodgkin lymphoma

Conditions: Hodgkin's Lymphoma

Summary: the main purpose of this protocol is to estimate the percentage of patients with intermediate risk hodgkin lymphoma who will survive free of disease (event-free survival) for three years after treatment with multi-agent chemotherapy (stanford v) and low-dose, tailored-field radiation therapy. the hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.

treatment plan description: adriamycin 25 mg/m2 iv day 1 of weeks 1, 3, 5, 7, 9, 11 vinblastine 6 mg/m2 iv day 1 of weeks 1, 3, 5, 7, 9, 11 nitrogen mustard 6mg/m2 iv on day 1 of weeks 1, 5, and 9 cyclophosphamide 650 mg/m2 iv day 1 of weeks 1, 5, 9(when nitrogen mustard was not available due to national shortage) vincristine 1.4 mg/m2 iv day 1 of weeks 2, 4, 6, 8, 10, 12 bleomycin 5 units/m2 iv day 1 of weeks 2, 4, 6, 8, 10, 12 etoposide 60 mg/m2 iv days 1,2 of weeks 3, 7, 11 prednisone\* 40 mg/m2/day divided in 3 doses po every other day of weeks 1-12 g-csf (only as needed in case of severe myelo-suppression requiring treatment delay) 5 mcg/kg sc days 3-13, 16-26, 29-39, 42-52, 55-65, 68-78 (as clinically indicated) \* prednisone taper is foreseen for the last 2 weeks of therapy. patients will be treated with 12 weeks of stanford v chemotherapy in the schedule outlined above. patients will then receive radiation therapy after completion of 12 weeks of chemotherapy. the radiation dose to individual nodal sites will be based on response after 8 weeks of chemotherapy: 15 gy for areas achieving a complete response and 25.5 gy achieving less than a complete response, or patients with bulky mediastinal mass.

Eligibility criteria:
inclusion criteria: * patient is less than or equal to 21 years of age * patient has a confirmed diagnosis of previously untreated hodgkin lymphoma * has ann arbor stage ib, iiia, or ia/iia with extranodal extension, multiple nodal involvement (3 or more sites), or bulky mediastinal adenopathy. exclusion criteria: * patients with favorable risk features * patients with unfavorable risk features * patients who have received prior therapy for hodgkin lymphoma.

Keywords: hodgkin's disease
a phase 3 open label extension study of fostamatinib disodium in the treatment of warm antibody autoimmune hemolytic anemia

Conditions: Warm Antibody Autoimmune Hemolytic Anemia

Summary: the primary objective of this study is: • to evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (waiha).


Eligibility criteria:
inclusion criteria: 1. subject must be willing and able to give written informed consent by signing an irb approved informed consent form prior to undergoing any study-specific procedures. 2. subject must have completed all 24 weeks of participation in the study c-935788-057. exclusion criteria: 1. any subject who discontinued participation in study c-935788-057 prior to week 24.

Keywords: waiha warm antibody autoimmune hemolytic anemia warm autoimmune hemolytic anemia
diabetes-specific formula (dsf) in individuals with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: a randomized, controlled, crossover design with three treatments to determine the effects of diabetes-specific formula on glycemic control in individuals with type 2 diabetes.


Eligibility criteria:
inclusion criteria participants are eligible to be included in the study only if all of the following criteria apply: 1. has type 2 diabetes as evidenced by use of oral antihyperglycemic medication(s). 2. bmi \> 18.5 and ≤ 35.0 kg/m2. 3. weight stable. 4. male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit. 5. if on chronic medication, the dosage to be constant for at least two months prior to screening visit and to maintain the medication and dose throughout the study. 6. willing to follow the protocol throughout the study. 7. at least a two-week washout period between completion of a previous research study and their start in the current study. 8. willing to refrain from taking non-study diabetes-specific formulas over the course of the study. 9. voluntarily signed and dated an informed consent form (icf) prior to any participation in the study. exclusion criteria participants are excluded from the study if any of the following criteria apply: 1. has a screening hba1c level \< 7% or ≥ 10%. 2. uses exogenous insulin for glucose control. 3. has confirmed type 1 diabetes and/or had history of diabetic ketoacidosis. 4. has current infection, inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or received antibiotics in the last 3 weeks. 5. has active malignancy. 6. has significant cardiovascular event within 6 months prior to study entry or history of congestive heart failure. 7. has end stage organ failure or was post organ transplant. 8. has a history of renal disease or severe gastroparesis. 9. has current hepatic disease. 10. has had bariatric surgery including gastric balloon; history of gastrointestinal disease or intestinal surgery that can interfere with consumption or digestion or absorption of study product. 11. has a chronic, contagious, infectious disease. 12. has eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures. 13. taking any herbals, dietary supplements or medications other than allowed anti-hyperglycemic medications, during the past four weeks prior to screening visit that could profoundly affect blood glucose or appetite. 14. uses diabetes-specific formula(s) defined as more than one eating occasion per week in the last three months. 15. has clotting or bleeding disorders. 16. participates in another study that has not been approved as a concomitant study by abbott nutrition. 17. has allergy or intolerance to any ingredient in the study product.